RT Book, Section A1 Chyou, Janice Y. A1 Sabatine, Marc S. A2 Murray, Michael F. A2 Babyatsky, Mark W. A2 Giovanni, Monica A. A2 Alkuraya, Fowzan S. A2 Stewart, Douglas R. SR Print(0) ID 1102698579 T1 Clopidogrel Pharmacogenomics T2 Clinical Genomics: Practical Applications in Adult Patient Care YR 2014 FD 2014 PB McGraw-Hill Education PP New York, NY SN 9780071622448 LK accessbiomedicalscience.mhmedical.com/content.aspx?aid=1102698579 RD 2024/03/29 AB Drug summary:Clopidogrel blocks the P2Y12 adenosine diphosphate (ADP) receptor on the surface of platelets and thus inhibits platelet activation.Despite established clinical efficacy, an inadequate response to clopidogrel has been observed in up to 30% of compliant patients. Such variability has been labeled as “clopidogrel nonresponsiveness,” “clopidogrel hyporesponsiveness,” and “clopidogrel resistance.”